Baseline characteristics
| Standard (n=89) | Web-based (n=91) | FENO-based (n=92) | |
|---|---|---|---|
| Age, years (SD) | 10.2 (3.2) | 10.6 (2.8) | 10.3 (2.9) |
| Male (%) | 61 (69) | 60 (66) | 62 (67) |
| Initial ICS dose (IQR) (µg) | 400 (400–800) | 400 (400–800) | 400 (400–800) |
| LABA use (%) | 40 (45) | 42 (46) | 44 (48) |
| LTRA use (%) | 11 (12) | 11 (12) | 12 (13) |
| FENO, ppb (IQR) | 21.4 (10.5–35.1) | 17.1 (10.0–30.0) | 15.4 (10.0–26.3) |
| FEV1, %pred (SD) | 93.9 (14.0) | 98.1 (12.6) | 95.2 (12.6) |
| FVC, %pred (SD) | 101.0 (13.0) | 103.3 (12.2) | 100.3 (12.8) |
| ACT or C-ACT score (SD) | 21.1 (3.3) | 22.1 (3.5) | 20.7 (4.3) |
| ACT≥20 | 62 (70) | 73 (81) | 60 (65) |
| Daily SABA, puffs (SD) | 0.4 (0.8) | 0.4 (0.8) | 0.6 (1.2) |
| Symptom-free days, (SD) | 54% (35) | 60% (33) | 53% (34) |
| PAQLQ score child (IQR) | 6.2 (5.9–6.6) | 6.3 (5.9–6.6) | 6.0 (5.6–6.6) |
| PACQLQ score parent (IQR) | 6.1 (5.8–6.8) | 6.7 (6.2–7.0) | 6.3 (5.7–6.8) |
| EQ-5D score (SD) | 0.913 (0.095) | 0.915 (0.092) | 0.922 (0.102) |
Data shown are numbers of patients (%), mean (SD) or median (IQR).
ACT, Asthma Control Test; C-ACT, Childhood ACT; EQ-5D, EuroQoL-5 dimensions; ICS, inhaled corticosteroids; LABA, long-acting β-agonist; LTRA, leukotriene receptor antagonist; %pred, percentage of predicted FEV1; PACQLQ, paediatric asthma-related caregiver quality of life questionnaire; PAQLQ, paediatric asthma-related quality of life questionnaire; SABA, short-acting β-agonist.